1
|
Faverio P, Maloberti A, Rebora P, Intravaia RCM, Tognola C, Toscani G, Amato A, Leoni V, Franco G, Vitarelli F, Spiti S, Luppi F, Valsecchi MG, Pesci A, Giannattasio C. Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis. High Blood Press Cardiovasc Prev 2024; 31:289-297. [PMID: 38739257 PMCID: PMC11161536 DOI: 10.1007/s40292-024-00638-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Accepted: 04/02/2024] [Indexed: 05/14/2024] Open
Abstract
INTRODUCTION Prevalence of cardiac and vascular fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF) has not been extensively evaluated. AIM In this study, we aimed to evaluate the heart and vessels functional and structural properties in patients with IPF compared to healthy controls. An exploratory analysis regarding disease severity in IPF patients has been done. METHODS We enrolled 50 patients with IPF (at disease diagnosis before antifibrotic therapy initiation) and 50 controls matched for age and gender. Heart was evaluated through echocardiography and plasmatic NT-pro-brain natriuretic peptide that, together with patients' symptoms, allow to define the presence of Heart Failure (HF) and diastolic dysfunction. Vessels were evaluated through Flow Mediated Dilation (FMD - endothelial function) and Pulse Wave Velocity (PWV-arterial stiffness) RESULTS: Patients with IPF had a prevalence of diastolic disfunction of 83.8%, HF of 37.8% and vascular fibrosis of 76.6%. No statistically significant difference was observed in comparison to the control group who showed prevalence of diastolic disfunction, HF and vascular fibrosis of 67.3%, 24.5% and 84.8%, respectively. Disease severity seems not to affect PWV, FMD, diastolic dysfunction and HF. CONCLUSIONS Patients with IPF early in the disease course do not present a significant CV fibrotic involvement when compared with age- and sex-matched controls. Bigger and adequately powered studies are needed to confirm our preliminary data and longitudinal studies are required in order to understand the time of appearance and progression rate of heart and vascular involvement in IPF subjects.
Collapse
Affiliation(s)
- Paola Faverio
- U.O.C. di Pneumologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Alessandro Maloberti
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy.
- Cardiology IV, ACardio Center, SST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20159, Milan, Italy.
| | - Paola Rebora
- School of Medicine and Surgery, Center of Biostatistics for Clinical Epidemiology, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Rita Cristina Myriam Intravaia
- Cardiology IV, ACardio Center, SST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20159, Milan, Italy
| | - Chiara Tognola
- Cardiology IV, ACardio Center, SST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20159, Milan, Italy
| | - Giorgio Toscani
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Anna Amato
- School of Medicine and Surgery, Center of Biostatistics for Clinical Epidemiology, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Valerio Leoni
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
- Laboratory of Clinical Pathology, Hospital Pio XI of Desio, ASST-Brianza, 20832, Desio, Italy
| | - Giovanni Franco
- U.O.C. di Pneumologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Federica Vitarelli
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
- Laboratory of Clinical Pathology, Hospital Pio XI of Desio, ASST-Brianza, 20832, Desio, Italy
| | - Simona Spiti
- Laboratory of Clinical Pathology, Hospital Pio XI of Desio, ASST-Brianza, 20832, Desio, Italy
| | - Fabrizio Luppi
- U.O.C. di Pneumologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Maria Grazia Valsecchi
- School of Medicine and Surgery, Center of Biostatistics for Clinical Epidemiology, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Alberto Pesci
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Cristina Giannattasio
- School of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy
- Cardiology IV, ACardio Center, SST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20159, Milan, Italy
| |
Collapse
|
2
|
Zhang W, Zhao N, Gao Y, Huang B, Wang L, Zhou X, Li Z. Automatic liver segmentation and assessment of liver fibrosis using deep learning with MR T1-weighted images in rats. Magn Reson Imaging 2024; 107:1-7. [PMID: 38147969 DOI: 10.1016/j.mri.2023.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 12/15/2023] [Accepted: 12/22/2023] [Indexed: 12/28/2023]
Abstract
OBJECTIVES To validate the performance of nnU-Net in segmentation and CNN in classification for liver fibrosis using T1-weighted images. MATERIALS AND METHODS In this prospective study, animal models of liver fibrosis were induced by injecting subcutaneously a mixture of Carbon tetrachloride and olive oil. A total of 99 male Wistar rats were successfully induced and underwent MR scanning with no contrast agent to get T1-weighted images. The regions of interest (ROIs) of the whole liver were delineated layer by layer along the liver edge by 3D Slicer. For segmentation task, all T1-weighted images were randomly divided into training and test cohorts in a ratio of 7:3. For classification, images containing the hepatic maximum diameter of every rat were selected and 80% images of no liver fibrosis (NLF), early liver fibrosis (ELF) and progressive liver fibrosis (PLF) stages were randomly selected for training, while the rest were used for testing. Liver segmentation was performed by the nnU-Net model. The convolutional neural network (CNN) was used for classification task of liver fibrosis stages. The Dice similarity coefficient was used to evaluate the segmentation performance of nnU-Net. Confusion matrix, ROC curve and accuracy were used to show the classification performance of CNN. RESULTS A total of 2628 images were obtained from 99 Wistar rats by MR scanning. For liver segmentation by nnU-Net, the Dice similarity coefficient in the test set was 0.8477. The accuracies of CNN in staging NLF, ELF and PLF were 0.73, 0.89 and 0.84, respectively. The AUCs were 0.76, 0.88 and 0.79, respectively. CONCLUSION The nnU-Net architecture is of high accuracy for liver segmentation and CNN for assessment of liver fibrosis with T1-weighted images.
Collapse
Affiliation(s)
- Wenjing Zhang
- Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Nan Zhao
- College of Computer Science and Technology of Qingdao University, Qingdao, China
| | - Yuanxiang Gao
- Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Baoxiang Huang
- College of Computer Science and Technology of Qingdao University, Qingdao, China
| | - Lili Wang
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Xiaoming Zhou
- Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Zhiming Li
- Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
| |
Collapse
|
3
|
Kozawa S, Tejima K, Takagi S, Kuroda M, Nogami-Itoh M, Kitamura H, Niwa T, Ogura T, Natsume-Kitatani Y, Sato TN. Latent inter-organ mechanism of idiopathic pulmonary fibrosis unveiled by a generative computational approach. Sci Rep 2023; 13:21981. [PMID: 38081956 PMCID: PMC10713585 DOI: 10.1038/s41598-023-49281-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 12/06/2023] [Indexed: 12/18/2023] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by complex lung pathogenesis affecting approximately three million people worldwide. While the molecular and cellular details of the IPF mechanism is emerging, our current understanding is centered around the lung itself. On the other hand, many human diseases are the products of complex multi-organ interactions. Hence, we postulate that a dysfunctional crosstalk of the lung with other organs plays a causative role in the onset, progression and/or complications of IPF. In this study, we employed a generative computational approach to identify such inter-organ mechanism of IPF. This approach found unexpected molecular relatedness of IPF to neoplasm, diabetes, Alzheimer's disease, obesity, atherosclerosis, and arteriosclerosis. Furthermore, as a potential mechanism underlying this relatedness, we uncovered a putative molecular crosstalk system across the lung and the liver. In this inter-organ system, a secreted protein, kininogen 1, from hepatocytes in the liver interacts with its receptor, bradykinin receptor B1 in the lung. This ligand-receptor interaction across the liver and the lung leads to the activation of calmodulin pathways in the lung, leading to the activation of interleukin 6 and phosphoenolpyruvate carboxykinase 1 pathway across these organs. Importantly, we retrospectively identified several pre-clinical and clinical evidence supporting this inter-organ mechanism of IPF. In conclusion, such feedforward and feedback loop system across the lung and the liver provides a unique opportunity for the development of the treatment and/or diagnosis of IPF. Furthermore, the result illustrates a generative computational framework for machine-mediated synthesis of mechanisms that facilitates and complements the traditional experimental approaches in biomedical sciences.
Collapse
Affiliation(s)
- Satoshi Kozawa
- Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan
- The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International (ATR), Kyoto, Japan
| | - Kengo Tejima
- Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan
- The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International (ATR), Kyoto, Japan
| | - Shunki Takagi
- Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan
- The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International (ATR), Kyoto, Japan
| | - Masataka Kuroda
- National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Mitsubishi Tanabe Pharma Corporation, Kanagawa, Japan
| | - Mari Nogami-Itoh
- National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - Hideya Kitamura
- Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan
| | - Takashi Niwa
- Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan
| | - Takashi Ogura
- Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan
| | - Yayoi Natsume-Kitatani
- National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan
| | - Thomas N Sato
- Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan.
- The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International (ATR), Kyoto, Japan.
- V-iCliniX Laboratory, Nara Medical University, Nara, Japan.
| |
Collapse
|
4
|
Shapanis A, Jones MG, Schofield J, Skipp P. Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis. Thorax 2023; 78:682-689. [PMID: 36808085 PMCID: PMC10314053 DOI: 10.1136/thorax-2022-219731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Accepted: 01/19/2023] [Indexed: 02/22/2023]
Abstract
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive disease with a median survival time of 3-5 years. Diagnosis remains challenging and disease progression varies greatly, suggesting the possibility of distinct subphenotypes. METHODS AND RESULTS We analysed publicly available peripheral blood mononuclear cell expression datasets for 219 IPF, 411 asthma, 362 tuberculosis, 151 healthy, 92 HIV and 83 other disease samples, totalling 1318 patients. We integrated the datasets and split them into train (n=871) and test (n=477) cohorts to investigate the utility of a machine learning model (support vector machine) for predicting IPF. A panel of 44 genes predicted IPF in a background of healthy, tuberculosis, HIV and asthma with an area under the curve of 0.9464, corresponding to a sensitivity of 0.865 and a specificity of 0.89. We then applied topological data analysis to investigate the possibility of subphenotypes within IPF. We identified five molecular subphenotypes of IPF, one of which corresponded to a phenotype enriched for death/transplant. The subphenotypes were molecularly characterised using bioinformatic and pathway analysis tools identifying distinct subphenotype features including one which suggests an extrapulmonary or systemic fibrotic disease. CONCLUSIONS Integration of multiple datasets, from the same tissue, enabled the development of a model to accurately predict IPF using a panel of 44 genes. Furthermore, topological data analysis identified distinct subphenotypes of patients with IPF which were defined by differences in molecular pathobiology and clinical characteristics.
Collapse
Affiliation(s)
- Andrew Shapanis
- Biological Sciences, University of Southampton, Southampton, Hampshire, UK
| | - Mark G Jones
- Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
| | | | - Paul Skipp
- Biological Sciences, University of Southampton, Southampton, Hampshire, UK
| |
Collapse
|
5
|
Guzy RD, Bollenbecker S, Krick S. From the Gut to the Lung: Evidence of Antifibrotic Activity of Endocrine Fibroblast Growth Factor 19. Am J Respir Cell Mol Biol 2022; 67:139-141. [PMID: 35580176 PMCID: PMC9348557 DOI: 10.1165/rcmb.2022-0057ed] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Robert D Guzy
- Department of Medicine The University of Chicago Chicago, Illinois
| | - Seth Bollenbecker
- Department of Medicine University of Alabama at Birmingham Birmingham, Alabama
| | - Stefanie Krick
- Department of Medicine University of Alabama at Birmingham Birmingham, Alabama
- Gregory Fleming James Cystic Fibrosis Research Center University of Alabama at Birmingham Birmingham, Alabama
| |
Collapse
|
6
|
Hyzny EJ, Chan EG, Morrell M, Harano T, Sanchez PG. A review of liver dysfunction in the lung transplant patient. Clin Transplant 2021; 35:e14344. [PMID: 33960530 DOI: 10.1111/ctr.14344] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 04/09/2021] [Accepted: 04/26/2021] [Indexed: 12/11/2022]
Abstract
Liver dysfunction is an increasingly common finding in patients evaluated for lung transplantation. New or worsening dysfunction in the perioperative period, defined by presence of clinical ascites/encephalopathy, high model for end-stage liver disease (MELD) score, and/or independent diagnostic criteria, is associated with high short- and long-term mortality. Therefore, a thorough liver function assessment is necessary prior to listing for lung transplant. Unfortunately, identification and intraoperative monitoring remain the only options for prevention of disease progression with isolated lung transplantation. Combined lung and liver transplantation may provide an option for definitive long-term management in selecting patients with known liver disease at high risk for postoperative progression. However, experience with the combined operation is extremely limited and indications for combined lung and liver transplant remain unclear. Herein, we present a comprehensive literature review of patients with liver dysfunction undergoing lung transplantation with and without concurrent liver transplant in an effort to illuminate the risks, benefits, and clinical judgement surrounding decision to pursue combined lung-liver transplantation (CLLT). We also argue description of liver function is currently a weakness of the current lung allocation scoring system. Additional algorithms incorporating liver function may aid in risk stratification and decision to pursue combined transplantation.
Collapse
Affiliation(s)
- Eric J Hyzny
- Division of Thoracic Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Ernest G Chan
- Division of Thoracic Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Matthew Morrell
- Pulmonary, Allergy, and Critical Care Medicine Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Takashi Harano
- Division of Thoracic Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Pablo G Sanchez
- Division of Thoracic Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| |
Collapse
|